

1 **Supplementary Figure Legends**

2 **Supplementary Figure 1:** Env quantitation of VLPs and Timeline of long-term immune study

3 (A) Western blot of recombinant HIV_{BAL} gp120 at the indicated concentrations and 3 independent
4 preparations of VLPs (8 mg/ml) diluted 1:200 in RIPA buffer. Densitometric measurement of
5 diluted VLPs yielded an average concentration of 56 ng/ml ($56 \text{ ng/ml} * 200 = 11.2 \text{ } \mu\text{g/ml}$
6 undiluted) (B) Timeline of vaccine regimen with prime, boosts, ICC, sera collection, and
7 sacrifice denoted by arrows and the number of weeks after initial prime (week 0).

8

9 **Supplementary Figure 2:** CD107a Membrane Localization (A) Percent of CD107a positive

10 PBMCs after stimulation for 5 hours with 2 $\mu\text{g/ml}$ HIV-1 consensus B Env peptide pool with
11 background subtraction (n = 10). (B) Percent of CD107a positive PBMCs after stimulation for 5
12 hours with 2 $\mu\text{g/ml}$ HIV-1 consensus B Gag peptide with background subtraction (n = 10). *
13 indicates $p < 0.05$ when compared to PBS control by either Student's unpaired t-test or Welch's t-
14 test in cases where F-test indicated unequal variance.

15

16

17

18

19


20

21

22

23



24 Supplementary Figure 1:



25

26

27



29

30